Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant n… Read more
Black Diamond Therapeutics Inc (BDTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.062x
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has a cash flow conversion efficiency ratio of -0.062x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($126.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Black Diamond Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Black Diamond Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Black Diamond Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BankFinancial Corporation
NASDAQ:BFIN
|
-0.017x |
|
Zhejiang Sunrise Garment Group Co Ltd
SHG:605138
|
N/A |
|
Global Water Resources Inc
NASDAQ:GWRS
|
0.097x |
|
Bonduelle SAS
LSE:0N75
|
0.187x |
|
Major-Power Technology Co., Ltd.
TWO:6720
|
-0.004x |
|
EKF DIAGNOST.HLDGS.LS-01
F:LYF
|
N/A |
|
Kofola CeskoSlovensko as
PR:KOFOL
|
0.222x |
|
GTC
F:G91
|
0.027x |
Annual Cash Flow Conversion Efficiency for Black Diamond Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Black Diamond Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $83.28 Million | $-62.30 Million | -0.748x | -30.89% |
| 2023-12-31 | $116.74 Million | $-66.72 Million | -0.572x | +22.28% |
| 2022-12-31 | $115.69 Million | $-85.08 Million | -0.735x | -43.85% |
| 2021-12-31 | $195.90 Million | $-100.15 Million | -0.511x | -201.71% |
| 2020-12-31 | $307.76 Million | $-52.15 Million | -0.169x | -132.38% |
| 2019-12-31 | $-47.16 Million | $-24.67 Million | 0.523x | -3.81% |
| 2018-12-31 | $-15.54 Million | $-8.45 Million | 0.544x | +54.44% |
| 2017-12-31 | $-6.67 Million | $-2.35 Million | 0.352x | -- |